Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

NCT02915016 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

334

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: DNA-HIV-PT123 vaccine
BIOLOGICAL: Bivalent Subtype C gp120/MF59 vaccine
BIOLOGICAL: Bivalent Subtype C gp120/AS01B vaccine
BIOLOGICAL: Placebo

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)